Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (C5ITs)

NCT04202341 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04202341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04202341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (C5ITs)
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Observational
Overall status
Recruiting
Start date
December 2, 2019
Completion date
October 1, 2029
Enrollment
500 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis